Stock 6662 BIOLASCO TAIWAN CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

BioLASCO Taiwan Co., Ltd. Share Price

Equities

6662

TW0006662000

Biotechnology & Medical Research

End-of-day quote Taipei Exchange
Other stock markets
 03:30:00 31/05/2024 am IST 		5-day change 1st Jan Change
36.2 TWD +1.26% Intraday chart for BioLASCO Taiwan Co., Ltd. +3.58% +9.04%
14/05 BioLASCO Taiwan Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
20/03 BioLASCO Taiwan Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Financials

Sales 2022 236M 7.29M 608M Sales 2023 265M 8.18M 682M Capitalization 850M 26.28M 2.19B
Net income 2022 42M 1.3M 108M Net income 2023 49M 1.51M 126M EV / Sales 2022 2.56 x
Net cash position 2022 161M 4.98M 416M Net cash position 2023 143M 4.43M 370M EV / Sales 2023 2.67 x
P/E ratio 2022
18.1 x
P/E ratio 2023
17.1 x
Employees 87
Yield 2022
5.03%
Yield 2023
4.97%
Free-Float 54.31%
More Fundamentals * Assessed data

Chart BioLASCO Taiwan Co., Ltd.

Dynamic Chart

Latest news about BioLASCO Taiwan Co., Ltd.

BioLASCO Taiwan Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
BioLASCO Taiwan Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
BioLASCO Taiwan Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
BioLASCO Taiwan Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
BioLASCO Taiwan Co., Ltd. Announces Cash Dividend CI
BioLASCO Taiwan Co., Ltd. Announces Change of Remuneration Committee CI
BioLASCO Taiwan Co., Ltd. Announces Change of Audit Committee CI
BioLASCO Taiwan Co., Ltd. Announces Board Changes CI
BioLASCO Taiwan Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
BioLASCO Taiwan Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
BioLASCO Taiwan Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
BioLASCO Taiwan Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
BioLASCO Taiwan Co., Ltd. Announces Cash Dividend, Payable on August 26, 2022 CI
BioLASCO Taiwan Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
BioLASCO Taiwan Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021 CI
More news

Press releases BioLASCO Taiwan Co., Ltd.

BioLASCO Taiwan : Financial Statements for the second quarter of 2022 approved by the board of directors PU
BioLASCO Taiwan : Announce the ex-dividend date and cash dividend payment date approved by the board of directors. PU
BioLASCO Taiwan : Announcement of important resolutions of 2022 Annual General Shareholders' Meeting of BioLASCO. PU
More press releases

Quotes and Performance

1 day+1.26%
1 week+3.58%
1 month+3.43%
3 months-6.22%
6 months+12.77%
Current year+9.04%
More quotes

Highs and lows

1 week
34.75
Extreme 34.75
36.20
1 month
33.55
Extreme 33.55
36.20
Current year
32.70
Extreme 32.7
39.50
1 year
30.40
Extreme 30.4
39.50
3 years
28.60
Extreme 28.6
39.50
5 years
25.25
Extreme 25.25
60.00
10 years
25.25
Extreme 25.25
71.09
More quotes

Managers and Directors - BioLASCO Taiwan Co., Ltd.

Managers TitleAgeSince
Chen Chung Chen CEO
 Chief Executive Officer - 09/01/09
Yue Ching Yu DFI
 Director of Finance/CFO - 01/14/01
Lei Yao Chang IRC
 Investor Relations Contact - -
Members of the board TitleAgeSince
Chen Chung Chen CEO
 Chief Executive Officer - 09/01/09
Li Chu Wu BRD
 Director/Board Member - 19/14/19
Chun Wei Chen BRD
 Director/Board Member - 22/17/22
More insiders

Quotes

Date Price Change Volume
31/24/31 36.2 +1.26% 16,001
30/24/30 35.75 -.--% 20,001
29/24/29 35.75 +0.99% 13,000
28/24/28 35.4 -0.14% 9,030
27/24/27 35.45 +1.43% 6,223

End-of-day quote Taipei Exchange, May 31, 2024

More quotes

Company Profile

BioLASCO Taiwan Co., Ltd. is a Taiwan-based company mainly engaged in the production of Specific Pathogen Free (SPF) laboratory animals and the high-value special-mode experimental animals, as well as the introduction and production of highly-applicable disease-mode animals. The company also provides equipment related to feeding, supplies and testing platform, life science research and pharmaceutical development services.
Sector
Biotechnology & Medical Research
More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
BIOLASCO TAIWAN CO., LTD. Stock BioLASCO Taiwan Co., Ltd.
+9.04% 28.51M
MODERNA, INC. Stock Moderna, Inc.
+43.36% 54.63B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-5.31% 39.92B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+14.75% 26.86B
CELLTRION, INC. Stock Celltrion, Inc.
-12.56% 26.22B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-22.45% 18.78B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+25.12% 12.21B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+0.04% 12.16B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+26.04% 11.94B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-11.83% 10.74B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. 6662 Stock